249 related articles for article (PubMed ID: 7685909)
1. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
[TBL] [Abstract][Full Text] [Related]
2. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity.
Baskar S; Nabavi N; Glimcher LH; Ostrand-Rosenberg S
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):209-15. PubMed ID: 8297902
[TBL] [Abstract][Full Text] [Related]
4. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of T cell response to tumors by targeting on costimulatory pathway.
Chen L
Leukemia; 1997 Apr; 11 Suppl 3():567-9. PubMed ID: 9209456
[TBL] [Abstract][Full Text] [Related]
6. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
Baskar S; Glimcher L; Nabavi N; Jones RT; Ostrand-Rosenberg S
J Exp Med; 1995 Feb; 181(2):619-29. PubMed ID: 7836917
[TBL] [Abstract][Full Text] [Related]
7. A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells.
Behar SM; Porcelli SA; Beckman EM; Brenner MB
J Exp Med; 1995 Dec; 182(6):2007-18. PubMed ID: 7500046
[TBL] [Abstract][Full Text] [Related]
8. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
[TBL] [Abstract][Full Text] [Related]
10. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
Ramarathinam L; Castle M; Wu Y; Liu Y
J Exp Med; 1994 Apr; 179(4):1205-14. PubMed ID: 7511683
[TBL] [Abstract][Full Text] [Related]
11. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.
Li Y; Hellstrom KE; Newby SA; Chen L
J Exp Med; 1996 Feb; 183(2):639-44. PubMed ID: 8627175
[TBL] [Abstract][Full Text] [Related]
12. An autologous self-antigen differentially regulates expression of I-A glycoproteins and B7 costimulatory molecules on CD4- CD8- T helper cells.
Walker MR; White GA; Nardella JP; Mannie MD
J Leukoc Biol; 1999 Jul; 66(1):120-6. PubMed ID: 10410999
[TBL] [Abstract][Full Text] [Related]
13. Alloantigen presentation by B cells: analysis of the requirement for B-cell activation.
Wilson JL; Cunningham AC; Kirby JA
Immunology; 1995 Nov; 86(3):325-30. PubMed ID: 8550066
[TBL] [Abstract][Full Text] [Related]
14. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adenovirus coexpressing covalent peptide/MHC class II complex and B7-1: in vitro and in vivo activation of myelin basic protein-specific T cells.
Chen J; Huber BT; Grand RJ; Li W
J Immunol; 2001 Aug; 167(3):1297-305. PubMed ID: 11466346
[TBL] [Abstract][Full Text] [Related]
16. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
[TBL] [Abstract][Full Text] [Related]
17. Restoration of alloreactivity of melanoma by transduction with B7.1.
Brady MS; Lee F; Eckels DD; Ree SY; Latouche JB; Lee JS
J Immunother; 2000; 23(3):353-61. PubMed ID: 10838664
[TBL] [Abstract][Full Text] [Related]
18. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.
Gimmi CD; Freeman GJ; Gribben JG; Gray G; Nadler LM
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6586-90. PubMed ID: 7688125
[TBL] [Abstract][Full Text] [Related]
19. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration.
Lang S; Whiteside TL; Lebeau A; Zeidler R; Mack B; Wollenberg B
Arch Otolaryngol Head Neck Surg; 1999 Jan; 125(1):82-8. PubMed ID: 9932594
[TBL] [Abstract][Full Text] [Related]
20. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
